The Power List 2019 – Business Captains
Chief Executive Officer, Roche Group
After completing his studies in economics and law at the University of Innsbruck in Austria, Severin, joined the Roche Group in 1993 as a trainee in corporate finance. Thirteen years later, he was appointed CEO of Roche’s Diagnostics Division, and in 2008 he became CEO of the Roche Group. The company’s cancer immunotherapy Tecentriq (atezolizumab), a PD-L1 inhibitor, this year became the first immunotherapy approved for breast cancer in the US.